title: Periodontal inflammation in renal transplant recipients receiving everolimus or tacrolimus - preliminary results.
abstract: OBJECTIVE
  To compare oral health status between renal transplant recipients (RTRs) receiving tacrolimus (Tac) or everolimus (ERL) as immunosuppressive therapy.
  
  
  METHODS
  This study is a cross-sectional study.
  
  
  METHODS
  Thirty-six RTRs receiving Tac and 22 RTRs receiving ERL were included in the study. Age, gender, time since transplant and pharmacological data were recorded for both groups. Oral health status was assessed through the evaluation of teeth, periodontal parameters as well as saliva flow rate and pH.
  
  
  RESULTS
  RTRs receiving ERL were older than those receiving Tac. No differences were found between groups concerning oral hygiene habits, oral symptoms, smoking habits, unstimulated and stimulated saliva flow rate and pH, clinical attachment level or the number of decayed, missing and filled teeth. However, RTRs receiving ERL presented lower visible plaque index and lower values for bleeding on probing when compared to RTRs receiving Tac. In addition, RTRs receiving ERL presented a gingival index varying from normal to moderate inflammation whereas RTRs receiving Tac presented a gingival index varying from mild to severe inflammation.
  
  
  CONCLUSIONS
  RTRs receiving ERL have lower periodontal inflammation when compared to RTRs receiving Tac.
authors: Department of Oral Medicine and Oral Surgery, Faculty of Dental Medicine, University of Porto, Portugal.
authors: O
authors: O
authors: Pereira-Lopes
authors: B
authors: B
authors: Sampaio-Maia
authors: S
authors: S
authors: Sampaio
authors: P
authors: P
authors: Vieira-Marques
authors: F
authors: F
authors: Monteiro-da-Silva
authors: A C
authors: AC
authors: Braga
authors: A
authors: A
authors: Felino
authors: M
authors: M
authors: Pestana
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D064591:Allografts / Q000637:transplantation*; D003430:Cross-Sectional Studies; D004245:DMF Index; D003774:Dental Plaque Index; D000068338:Everolimus; D005260:Female; D005884:Gingival Hemorrhage / Q000145:classification; D006304:Health Status; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009909:Oral Health; D009910:Oral Hygiene; D017622:Periodontal Attachment Loss / Q000145:classification; D010512:Periodontal Index; D010518:Periodontitis / Q000145:classification; D012463:Saliva / Q000378:metabolism / Q000502:physiology; D012636:Secretory Rate / Q000502:physiology; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012907:Smoking; D016559:Tacrolimus / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus; D016559:Tacrolimus
keywords: calcineurin inhibitors; everolimus; mTOR inhibitors; oral health; periodontal disease; renal transplant recipients; tacrolimus